Abstract:Context: Chronic inflammation has been linked to cancer since the 19th century. Tumor growth is supported by the proangiogenic factors that chronic inflammation requires. Polarized leukocytes initiate these angiogenic and tumorigenic factors. TIPE2, a transport protein, manages the cytoskeletal rearrangement that gives a polarized leukocyte its motility. Inhibition of this protein could lead to a therapeutic option for solid tumor cancers; however, no such inhibitors have been developed so far due to the large cavity size of the TIPE2 protein. Here we have examined possible small molecule inhibitors by combining structure-based and fragment-based drug design approaches. The highest binding ligands were complexed with the protein, and fragment libraries were docked with the complex with the intention of linking the hit compounds and fragments to design a more potent ligand. Three hit compounds were identified by in silico structure-based screening and a linked compound, C2–F14, of excellent binding affinity, was identified by linking fragments to the hit compounds. C2–F14 demonstrates good binding stability in molecular dynamic simulations and great predicted ADME properties. Methods: High throughput molecular docking calculations of mass libraries were performed using AutoDock Vina 1.1.2. Molecular docking of individual ligands was performed using AutoDock Vina with PyRx. Ligand libraries were prepared using OpenBabel, linked ligands were prepared using Avogadro. The protein was prepared using AutoDockTools-1.5.6. Protein-ligand complexes were visualized with PyMOL. Two- and three-dimensional representations of protein–ligand interactions were plotted with BIOVIA Discovery Studio Visualizer. In silico absorption, distribution, metabolism, and excretion (ADME) properties were calculated using SwissADME. Molecular dynamics simulations were conducted with GROMACS.

Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 Via Structure-Based Virtual Screening and Biological Evaluation in in Vitro Models

In Silico Exploration for Novel Type-I Inhibitors of Tie-2/TEK: the Performance of Different Selection Strategy in Selecting Virtual Screening Candidates.

Pyridyl-Pyrimidine Benzimidazole Derivatives As Potent, Selective, and Orally Bioavailable Inhibitors of Tie-2 Kinase

Discovery of Novel Anti-Angiogenesis Agents. Part 8: Diaryl Thiourea Bearing 1H-Indazole-3-amine As Multi-Target RTKs Inhibitors

Discovery of Novel Anti-Angiogenesis Agents. Part 7: Multitarget Inhibitors of VEGFR-2, TIE-2 and EphB4.

Alkynylpyrimidine Amide Derivatives As Potent, Selective, and Orally Active Inhibitors of Tie-2 Kinase.

In Silico Study of Potential Small Molecule TIPE2 Inhibitors for the Treatment of Cancer

Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes

Design and discovery of new selective and potent VEGF receptor 2 tyrosine kinase inhibitors

An Integrated Deep Learning and Molecular Dynamics Simulation-Based Screening Pipeline Identifies Inhibitors of a New Cancer Drug Target TIPE2

Identification of Novel PD-1/PD-L1 Small Molecule Inhibitors: Virtual Screening, Synthesis and in Vitro Characterisation

Anti-Angiogenic Therapy: Strategies to Develop Potent VEGFR-2 Tyrosine Kinase Inhibitors and Future Prospect

Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors

Discovery of Novel Anti-Angiogenesis Agents. Part 10: Multi-target Inhibitors of VEGFR-2, Tie-2 and EphB4 Incorporated with 1,2,3-Triazol

Synthesis, structural analysis, and SAR studies of triazine derivatives as potent, selective Tie-2 inhibitors.

Novel Multi-Target Angiogenesis Inhibitors As Potential Anticancer Agents: Design, Synthesis and Preliminary Activity Evaluation.

Design, synthesis and biological evaluation of biphenyl urea derivatives as novel VEGFR-2 inhibitors

Small molecule inhibitors of SHP2 tyrosine phosphatase discovered by virtual screening

Design, Synthesis and Biological Evaluation of Tanshinone IIA-based Analogues: Potent Inhibitors of Microtubule Formation and Angiogenesis

Protein–ligand Interaction-Guided Discovery of Novel VEGFR-2 Inhibitors

Discovery of Novel VEGFR-2 Inhibitors. Part 5: Exploration of Diverse Hinge-Binding Fragments Via Core-Refining Approach